Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL28297573 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL28918498 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL1792710 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL1134753 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL5161896 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL468813 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL6662558 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL15463836 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL2487171 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL11313361 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9282735-B2 | Use of EDDS and calcium ions as enchancers of molluscicidal activity | INNOSPEC LIMITED (GB) | 2016-03-15 | — | — | US | claimed |
| US-20150237850-A1 | COMPOSITION, METHOD AND USE | W. NEUDORFF GMBH KG (DE) | 2015-08-27 | — | — | US | claimed |
| EP-2389065-B1 | USE OF EDDS AND CALCIUM IONS AS ENHANCERS OF MOLLUSCICIDAL ACTIVITY | INNOSPEC LTD (GB) | 2015-08-19 | — | — | EP | claimed |
| US-9044009-B2 | Use of EDDS and calcium ions as enhancers of molluscicidal activity | W.NEUDORFF GMBH KG (DE) | 2015-06-02 | — | — | US | claimed |
| US-20120027832-A1 | USE OF EDDS AND CALCIUM IONS AS ENHANCERS OF MOLLUSCICIDAL ACTIVITY | W. NEUDORFF GMBH KG (DE) | 2012-02-02 | — | — | US | claimed |
| EP-2389065-A2 | USE OF EDDS AND CALCIUM IONS AS ENHACERS OF MOLLUSCICIDAL ACTIVITY | Innospec Limited (GB) | 2011-11-30 | — | — | EP | claimed |
| WO-2010084361-A2 | COMPOSITION, METHOD AND USE | INNOSPEC LIMITED (GB) | 2010-07-29 | — | — | WO | claimed |
| CN-1163126-C | Enhancement of metal molluscicides by ethylene diamine disuccinic acid | W����ŵ�� | 2004-08-25 | — | — | CN | claimed |
| US-20020136751-A1 | Naturally occurring enhancer of metal toxicants in molluscs | PURITCH GEORGE S (CA) | 2002-09-26 | — | — | US | claimed |
| EP-1052899-B1 | Enhancement of metal molluscicides by ethylene diamine disuccinic acid (EDDS) | NEUDORFF W GMBH KG (DE) | 2002-04-17 | — | — | EP | claimed |
| US-6352706-B1 | IRON, COPPER, ZINC AND/OR ALUMINUM COMPOUND; ETHYLENEDIAMINE DISUCCINIC ACID OR SALT OR COMPLEX THEREOF; AND CARRIER; STOMACH POISON | W. NEUDORFF GMBH KG (DE) | 2002-03-05 | — | — | US | claimed |
| CN-1290125-A | Enhancement of metal molluscicides by ethylene diamine disuccinic acid | NEUDORFF W GMBH KG (DE) | 2001-04-04 | — | — | CN | claimed |
| EP-1052899-A1 | ENHANCEMENT OF METAL MOLLUSCICIDES BY ETHYLENE DIAMINE DISUCCINIC ACID | W. NEUDORFF GmbH KG (DE) | 2000-11-22 | — | — | EP | claimed |
| WO-1999039576-A1 | ENHANCEMENT OF METAL MOLLUSCICIDES BY ETHYLENE DIAMINE DISUCCINIC ACID | W. NEUDORFF GMBH KG (DE) | 1999-08-12 | — | — | WO | claimed |
| EP-3701800-A1 | USE | Barry Callebaut AG (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10701951-B2 | Process of producing cocoa shell powder | BARRY CALLEBAUT AG (CH) | 2020-07-07 | — | — | US | disclosed |
| US-10477877-B2 | Cocoa shell powder and process of making | BARRY CALLEBAUT AG (CH) | 2019-11-19 | — | — | US | disclosed |
| WO-1999039576-A1 | ENHANCEMENT OF METAL MOLLUSCICIDES BY ETHYLENE DIAMINE DISUCCINIC ACID | W. NEUDORFF GMBH KG (DE) | 1999-08-12 | — | — | WO | disclosed |
| EP-0912095-A1 | PHOSPHATE COMPOSITION AND ITS UTILIZATION | Dzneladze, David (GE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997047201-A1 | PHOSPHATE COMPOSITION AND ITS UTILIZATION | DZNELADZE, DAVID (GE) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150237850-A1 | COMPOSITION, METHOD AND USE | IDUA, ATP2A3, ATP2A1 | LMNA 972/4885ALDH1A1 3649/4885SMN1; SMN2 406/4885 |
| US-20120027832-A1 | USE OF EDDS AND CALCIUM IONS AS ENHANCERS OF MOLLUSCICIDAL ACTIVITY | ORAI1, ATP2A1, ACMSD | LMNA 2161/4885ALDH1A1 3593/4885SMN1; SMN2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.